Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with heterogenous
presentation and often immense patient burden. Safe, targeted treatment options are …

Atopic dermatitis (AD) is a chronic, inflammatory, pruritic form of dermatosis with
heterogeneous manifestations that can substantially affect patients' quality of life. AD has a …

Background There is a great unmet need for advanced therapies that provide rapid, robust,
and sustained disease control for patients with ulcerative colitis. We assessed the efficacy …

The evidence‐and consensus‐based guideline on atopic eczema was developed in
accordance with the EuroGuiDerm Guideline and Consensus Statement Development …

Importance Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease with an
unmet need for treatments that provide rapid and high levels of skin clearance and itch …

The evidence‐and consensus‐based guideline on atopic eczema was developed in
accordance with the EuroGuiDerm Guideline and Consensus Statement Development …

Background Systemic therapies are typically combined with topical corticosteroids for the
management of moderate-to-severe atopic dermatitis. Upadacitinib is an oral Janus kinase …

Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a
spectrum of burdensome dermatologic conditions. The US Food and Drug Administration …

Importance Systemic treatments for atopic dermatitis are being evaluated primarily in
placebo-controlled trials; network meta-analysis can provide relative efficacy and safety …

Objective To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis
(RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD) …